<DOC>
	<DOCNO>NCT01228266</DOCNO>
	<brief_summary>The study randomize Phase II study , mask crossed-over placebo evaluate safety tolerability autologous mesenchymal stem cell transplantation patient active multiple sclerosis</brief_summary>
	<brief_title>Mesenchymal Stem Cell Transplantation MS</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<criteria>1 . Inflammatory form MS 1 . Relapsingremitting MS ( RRMS ) patient 2 . Secondary progressive MS ( SPMS ) patient continue relapse 3 . Primary progressive MS ( PPMS ) patient enhance MRI lesion positive CSF ( oligoclonal banding ) 2 . Age 1850 year 3 . Disease duration &gt; = 2 &gt; = 10 year 4 . EDSS 3.0 6.5 5 . Progression , continue relapse worsen MRI least year attempt therapy evidence : 1 . Increase &gt; = 1 EDSS point ( baseline EDSS &lt; = 5.0 ) 0.5 EDSS point ( baseline EDSS &gt; = 5.5 ) , quantifiable , objective evidence equivalent progression 2 . &gt; = 1 moderatesevere relapse past 18 month 3 . &gt; = 1 Gadolinium enhance lesion ( double triple dose Gadolinium ) 4 . &gt; = 1 new T2 lesion 5 . For PPMS , &gt; = 1 Gadolinium enhance lesion 6 . Has give inform consent participate study . 1 . SPMS without ongoing relapse 2 . PPMS without positive CSF Gadolinium enhance lesion 3 . &lt; = 3 month since treatment immunosuppressive therapy 4 . &lt; =1 month since last treatment interferonB glatiramer acetate 5 . Corticosteroid treatment &lt; = 30 day 6 . Relapse &lt; = 60 day 7 . History cancer clinical laboratory result indicative severe systemic disease , include infection HIV , Hepatitis B C 8 . Any metallic electronic device precludes undergo MRI 9 . Pregnancy lactation 10 . Current treatment investigational therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>Multiple Sclerosis</keyword>
</DOC>